Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aladorian SCHEMBL3423110 | 1.00 | RYR2 (1.00) | RYR2 | |
| SCHEMBL6867443 | 0.91 | RYR2 (0.83) | RYR2 | |
| SCHEMBL3428995 | 0.91 | RYR2 (0.83) | RYR2 | |
| SCHEMBL8127233 | 0.90 | RYR2 (0.81) | RYR2 | |
| SCHEMBL4112259 | 0.90 | RYR2 (1.00) | RYR2 | |
| SCHEMBL12777288 | 0.90 | RYR2 (0.81) | RYR2 | |
| SCHEMBL807117 | 0.88 | RYR2 (0.79) | RYR2 | |
| SCHEMBL26344260 | 0.88 | RYR2 (0.78) | RYR2 | |
| SCHEMBL806687 | 0.87 | RYR2 (1.00) | RYR2 | |
| SCHEMBL3428542 | 0.87 | RYR2 (0.77) | RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250255882-A1 | TREATMENT OF CARDIAC CONDITION RELATED COGNITIVE DYSFUNCTION | UNIV COLUMBIA (US) | 2025-08-14 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-3302442-B1 | DOSAGE FORMS AND USE THEREOF | TRIASTEK INC (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-12102721-B2 | Dosage forms of controlled release at specific gastrointestinal sites | Triastek, Inc. (CN) | 2024-10-01 | — | — | US | disclosed |
| US-12042562-B2 | 3D printing methods for compartmented pharmaceutical dosage forms | Triastek, Inc. (CN) | 2024-07-23 | — | — | US | disclosed |
| CN-116018131-A | Fast orodispersible tablet with inner cavity | 阿普雷奇亚制药有限责任公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11548928-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2023-01-10 | — | — | US | disclosed |
| US-11518796-B2 | Engineered platelets for targeted delivery of a therapeutic agent | JPV01 LTD. (GB) | 2022-12-06 | — | — | US | disclosed |
| US-11433022-B2 | Rapidly-orodispersible tablets having an in interior cavity | Aprecia Pharmaceuticals LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220251165-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-4026898-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | RYR2 3907/4885 |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | RYR2 2022/4885 |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | CYP2D6, CYP3A5, CYP2F1 | RYR2 3759/4885 |
| US-12042562-B2 | 3D printing methods for compartmented pharmaceutical dosage forms | CYP3A43, HTR3D, CYP3A7 | RYR2 4049/4885 |
| US-20250255882-A1 | TREATMENT OF CARDIAC CONDITION RELATED COGNITIVE DYSFUNCTION | CACNA1F, CACNA1S, RYR2 | RYR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.